$SEER News

Seer Files Complaint Against Nanomics At The ITC, With Brigham And Women's Hospital Joining In

Seer Rejects Proposed $2.40/Share Acquisition Offer From Bradley L. Radoff And Michael Torok

Seer, Inc. 2026 Q1 - Results - Earnings Call Presentation

Radoff-JEC Group Submits Third Offer To Acquire Seer For $2.40 Per Share In Cash Plus One Contingent Value Right

Seer, Inc. (SEER) Q1 2026 Earnings Call Transcript

Seer Affirms FY2026 Sales Guidance of $16.000M-$18.000M vs $17.050M Est

Full Transcript: Seer Q1 2026 Earnings Call

Seer Q1 EPS $(0.30) Misses $(0.29) Estimate, Sales $2.793M Miss $3.600M Estimate

Seer Files Patent Infringement Suit Against Nanomics Biotechnology

Canaccord Genuity Initiates Coverage On Seer with Buy Rating, Announces Price Target of $4

Seer Announces That Its Board Reviewed And Unanimously Rejected The Revised Unsolicited, Non-Binding Proposal From Radoff-JEC Group

Seer Announces Nonbinding Takeover Proposal From Shareholder Radoff-JEC Group At $2.35 Per Share In Cash Plus One Contingent Value Right

Seer Inc. Confirms Unsolicited $2.25/Share Takeover Proposal And Board Challenge From Radoff-JEC Group

Seer Inc. Confirms Unsolicited $2.25/Share Takeover Proposal And Board Challenge From Radoff-JEC Group

Seer Shares Jump On Takeover Proposal

Seer shares are trading higher after the company announced that the Radoff-JEC Group submitted a non-binding proposal to acquire the company.

The Radoff-JEC Group Submits Non-Binding Proposal To Acquire Seer For $2.25/Share

Seer Says Its Proteograph Platform Will Be Deployed To Generate High-Resolution Proteomic Data, Enhancing Insights From One Of The Largest Multi-omic Population Health Studies In Singapore

Seer Announced That The Patent Trial And Appeal Board Of The U.S. Patent And Trademark Office Issued A Final Written Decision On March 23, 2026, In An Inter Partes Review Of U.S. Patent No. 11,435,360 B2

Seer shares are trading lower after the company reported mixed Q4 financial results and issued FY26 sales guidance below estimates.